文献速递甲状腺核医学肿瘤 PET/CT

PSMA表达与[18F]FDG PET/CT在预测甲状腺癌结局中的互补作用:从黑白到灰色,精准肿瘤学时代

The complementary role of PSMA expression and [18F]FDG PET/CT in predicting thyroid cancer outcome: from black and white to shades of gray, in the era of precision oncology.
PubMed 文献 · EJNMMI Res · 2023-06-01

回顾性纳入23例甲状腺癌患者,评估原发灶PSMA免疫染色与[18F]FDG PET/CT对疾病复发、碘难治性(RAI-R)及末次随访状态的预测价值。PSMA表达与[18F]FDG摄取似乎具有互补预后作用;PET/CT阳性者PSMA染色均阳性,PET/CT阴性者中部分PSMA高表达者虽可复发但未出现RAI-R。

要点

  • 23例中18例复发,12/18例出现RAI-R,13/18例末次随访时有疾病证据。
  • PET/CT阳性9/12例RAI-R者和10/13例末次随访有疾病者,且所有PET/CT阳性者PSMA染色均阳性。
  • PET/CT阴性者中4/11例PSMA高表达(≥70%),3例复发但无一RAI-R,仅1例末次随访持续疾病。

核心结论

  • 原发肿瘤PSMA表达与[18F]FDG摄取似乎在甲状腺癌中发挥互补的预后作用。
  • 表达PSMA的大多数患者出现复发。
  • 在ATA中危组中,PSMA免疫染色阴性者复发少于表达PSMA者。
  • 尽管[18F]FDG PET/CT阴性者长期结局良好,PSMA评估可能有助于及时识别复发风险较高的受试者。

研究设计与样本

  • 回顾性队列研究,从甲状腺癌患者队列中筛选符合条件者:在本机构行甲状腺切除术、有原发肿瘤组织PSMA免疫染色、有[18F]FDG PET/CT及随访数据。
  • 共纳入23例受试者;PSMA染色采用视觉评估。
  • PET/CT阳性定义为经细胞学/组织学或随访证实的甲状腺癌部位[18F]FDG摄取高于背景。
  • 结局终点包括疾病复发、碘难治性(RAI-R)及末次随访(LFU)时状态。

主要发现

  • 疾病复发发生于18例患者(中位时间11个月,范围1-40);其中12/18例出现RAI-R(中位时间28个月,范围2-221),13/18例末次随访时有疾病证据。
  • PSMA表达阴性6/23例;PET/CT阴性11/23例(其中7/11例经历复发)。
  • PET/CT阳性9/12例RAI-R患者和10/13例末次随访有疾病证据者。
  • 所有PET/CT阳性患者PSMA免疫染色均阳性;PET/CT阴性11例中6例免疫染色阳性,其PSMA表达较低(中位评分30%,范围0-80%),低于PET/CT阳性者。
  • 无PSMA表达的肿瘤样本属于PET/CT亦阴性的患者(3例复发,2例RAI-R,1例末次随访有疾病)。

关键数值与推荐

  • PET/CT阳性定义:经细胞学/组织学或随访证实的甲状腺癌部位[18F]FDG摄取高于背景。
  • PSMA免疫染色采用视觉评估;PET/CT阴性但免疫染色阳性者PSMA中位评分30%(范围0-80%)。
  • PSMA高表达定义为≥70%,见于4/11例PET/CT阴性患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The value of Prostate Specific Membrane Antigen (PSMA) in thyroid carcinoma (TC) is still unknown. We aimed to test the potential complementary role of PSMA expression and 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) uptake on PET/CT as biomarkers for TC outcome prediction. MATERIALS AND METHODS: From a retrospective cohort of TC patients we selected those fulfilling the following inclusion/exclusion criteria: thyroidectomy in our Institution, available primary tumor tissue PSMA immunostaining, [18F]FDG PET/CT and follow-up data. PSMA staining was visually assessed. PET/CT was considered positive in case of [18F]FDG uptake higher than the background at the site of TC confirmed by cyto-/histology, and/or follow-up. Disease recurrence, radioiodine refractoriness (RAI-R) and status at last follow-up (LFU) were used as outcome endpoints. RESULTS: We included 23 subjects. Disease recurrence occurred in 18 patients (median time 11 months, range 1-40); among these 12/18 developed RAI-R (median time 28 months, range 2-221), and 13/18 had evidence of disease at LFU. PSMA expression was negative in 6/23 cases. PET/CT was negative in 11/23 patients (7/11 experienced recurrence). PET/CT was positive in 9/12 patients showing RAI-R and 10/13 cases with evidence of disease at LFU. All patients with positive PET/CT had a positive PSMA immunostaining. Six out of 11 patients with negative PET/CT were positive at immunostaining, showing lower PSMA expression (median score of 30%, range 0-80%) than patients with positive PET/CT. The TC samples without PSMA expression belonged to patients who resulted negative also at PET/CT (3 experienced recurrence, 2 were RAI-R, and 1 had disease at LFU). Four out of 11 patients who resulted negative at PET/CT exhibited very high PSMA expression (≥ 70%) and although 3 of them experienced recurrence, none resulted RAI-R, and only 1 had persistent disease at LFU. CONCLUSIONS: Primary tumor PSMA expression and [18F]FDG uptake seem to play a complementary prognostic role in TC. The majority of patients who expressed PSMA recurred. In the intermediate ATA risk class, patients with negative PSMA immunostaining recurred less than patients expressing PSMA. Additionally, although patients with a negative [18F]FDG PET/CT had a favourable long-term outcome, PSMA assessment might be useful to timely identify subjects at higher risk of recurrence.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Sollini M, Kirienko M, di Tommaso L, et al. The complementary role of PSMA expression and [18F]FDG PET/CT in predicting thyroid cancer outcome: from black and white to shades of gray, in the era of precision oncology. EJNMMI Res. 2023. PMID: 37261582. doi:10.1186/s13550-023-01004-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。